Patrice Rioux

Shareholder

CA·SEDI

Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)

Cumul. flow

Total declarations

Company

▲ Purchases (4 ops.)

€15k

▼ Sales (0 ops.)

—

Latest filing published 20 May 2024 for Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation), €4,324.

Filing timeline

BuySale

Patrice Rioux

Insider track record

Disclosed buys

Disclosed sells

Signal history

Patrice Rioux: trading record in brief

Patrice Rioux discloses dealings in Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) to SEDI. Between 29 March 2023 and 5 February 2024, the trades on record add up to 4 filings.

No open-market sale appears; the market trades are 4 purchases worth €15k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2024, the count stands at 4 purchases and no sales.

A typical purchase (the median) is worth €2,921.

On 20 May 2024 came the latest disclosure, an open-market purchase for €4,324 in Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation). Source: insider filings from SEDI. Past trades are no guide to future returns.

Companies and markets linked to Patrice Rioux

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) (CA)

Declarations4 total

▲

Patrice Rioux

3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of IssuerExecutives29 Mar 2023Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)

6,360 CAD0SEDI

12,000 shares@ CA$0.53Common SharesTSXSEDI:4316538

Canonical exit: 27 Jun 2023 (T+90)

▲

Patrice Rioux

3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of IssuerExecutives31 Mar 2023Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)

2,240 CAD0SEDI

4,000 shares@ CA$0.56Common SharesTSXSEDI:4316539

Canonical exit: 29 Jun 2023 (T+90)

▲

Patrice Rioux

3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of IssuerExecutives5 Feb 2024Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)

13,120 CAD19SEDI

16,000 shares@ CA$0.8298.8% of flowCommon SharesTSXSEDI:4316540

Canonical exit: 5 May 2024 (T+90)

▲

Patrice Rioux

3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of IssuerExecutives5 Feb 2024Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)

164 CAD11SEDI

200 shares@ CA$0.821.2% of flowCommon SharesTSXSEDI:4316541

Canonical exit: 5 May 2024 (T+90)

4 of 4 declarations

Patrice Rioux: trading record in brief

Patrice Rioux discloses dealings in Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) to SEDI. Between 29 March 2023 and 5 February 2024, the trades on record add up to 4 filings.

A typical purchase (the median) is worth €2,921.

Patrice Rioux

Insider track record

Patrice Rioux: trading record in brief

Companies and markets linked to Patrice Rioux

Related entities

Patrice Rioux

Insider track record

Patrice Rioux: trading record in brief

Companies and markets linked to Patrice Rioux

Related entities